Biobanking Services Market to Reach USD 81.68 Billion by 2033 | CAGR 5.4% | North America Leads with 40% Share | Key Players: Thermo Fisher Scientific, Tecan Trading AG, QIAGEN, Harrow Green Limited

Biobanking Services Market: Industry Outlook

The global biobanking services market reached US$ 48.56 billion in 2023, rising to US$ 51.00 billion in 2024, and is projected to reach US$ 81.68 billion by 2033, growing at a CAGR of 5.4% during 2025-2033. The market is expanding rapidly due to the rising demand for high-quality biospecimens that support personalized medicine, drug discovery, and translational research. Biobanks play a critical role in genomics, clinical trials, and epidemiological studies, making them essential for modern healthcare research. Growth is being driven by increased investments from both government and private organizations, the rising prevalence of chronic and rare diseases, and the expansion of precision medicine initiatives.

Technological innovations such as automated storage systems, AI-driven sample tracking, and virtual biobanking platforms are improving efficiency, accessibility, and data management. Furthermore, strategic collaborations among academic institutions, pharmaceutical companies, and contract research organizations are accelerating biobank development across regions. North America is emerging as a significant growth hub due to its expanding healthcare ecosystem, supportive government initiatives, and genetically diverse population, positioning the region at the forefront of biobanking services adoption.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):-https://www.datamintelligence.com/download-sample/biobanking-services-market?Juli

Recent Developments

✅ July 2025: UK Biobank announced plans to relocate over 11 million samples to a new automated facility in Manchester equipped with next‐generation robotic freezers, significantly boosting sample storage capacity and retrieval speeds.

✅ May 2025: Biobank operators expanded ultra‐low temperature storage capabilities at key facilities in Europe, enabling scalable, regulatory‐compliant storage solutions from -60°C to -196°C to support diverse research requirements.

✅ April 2025: Thermo Fisher Scientific committed USD 2 billion toward innovation and manufacturing expansion in the U.S., with substantial investment in R&D and advanced biobanking technologies to strengthen healthcare supply chains.

✅ March 2025: Teknova and Pluristyx introduced the PluriFreeze cryopreservation system, designed to enhance preservation performance for cell therapy development and other advanced biomedical applications.

✅ June 2025: Elucidata partnered with Sapien Biosciences to convert extensive biospecimen assets into AI‐ready multimodal data products, reinforcing the industry's shift toward combining biobanking with predictive analytics and big data.

Mergers & Acquisitions

✅ 2025: Regeneron Pharmaceuticals completed the acquisition of 23andMe's biobank and genetics services business for approximately US$256 million, gaining access to a large genomic dataset to advance drug discovery and biobank-related research.

✅ 2025: A leading biobanking and bioprocessing company acquired a UK-based biospecimen storage specialist to expand its European footprint and strengthen its global sample storage and logistics capabilities.

✅ 2025: Qiagen expanded its service offerings through the acquisition of a smaller biobanking firm specializing in sample preservation technologies, broadening its portfolio in automated biobank workflows and sample integrity solutions.

✅ 2024: Miltenyi Biotec acquired a biobank management software provider to accelerate end-to-end automation and integrate enhanced sample tracking with its cell processing platforms.

✅ 2024: A major biobank operator acquired a virtual biobanking services provider, enabling it to expand digital sample management and data-centric biobanking solutions across multiple research markets.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=biobanking-services-market?Juli

Key Players

• Thermo Fisher Scientific Inc. - A leading provider of biobanking solutions, offering automated storage systems, cryogenic equipment, and comprehensive sample management platforms for research and clinical applications.

• Tecan Trading AG - Specializes in laboratory automation and liquid handling solutions, supporting high-throughput sample processing and efficient biobank workflows.

• QIAGEN - Provides biobanking services, sample preservation technologies, and integrated genomics solutions to accelerate drug discovery and translational research.

• Harrow Green Limited - Offers global relocation, logistics, and management services for biobanking facilities, ensuring secure and compliant specimen handling.

• TTP Labtech - Delivers innovative automation systems and laboratory technologies for high-throughput biobank sample processing and storage.

• UHN Biospecimen Services - A prominent biobank service provider focused on human biospecimen collection, storage, and distribution for research and clinical studies.

• VigiSolvo - Offers digital and cloud-enabled solutions for biobank sample tracking, inventory management, and regulatory compliance.

• Sampled - Provides integrated biobanking services, including specimen collection, processing, and secure storage for clinical and research applications.

• Crown Bioscience Company (Indivumed Services) - Offers comprehensive biobank services, including biospecimen management, bioinformatics, and support for translational medicine and drug development programs.

Market Segmentation
By service type, human tissue biobanking leads with around 35% share, driven by demand for high-quality tissue samples in clinical research, translational studies, and personalized medicine. Stem cell biobanking accounts for approximately 25%, supported by growth in regenerative medicine and cell therapy applications. DNA/RNA biobanking represents about 20%, enabling genomics research, biomarker discovery, and precision medicine initiatives. Cord blood biobanking contributes roughly 10%, driven by increasing awareness of its potential in stem cell therapy. The remaining 10% comprises other specialized services, including microbial, plant, and veterinary biobanking.

By sample type, blood products dominate with about 40% share, as blood-based specimens are widely used for diagnostics, clinical trials, and genomics research. Human tissues account for roughly 30%, supporting cancer, rare disease, and personalized medicine studies. Cell lines contribute approximately 20%, primarily for drug screening and preclinical research, while nucleic acids (DNA/RNA) represent around 10% of the market, used in sequencing, genomics, and molecular biology research.

By application, regenerative medicine leads with 40% share, reflecting the growing use of stem cells and tissue samples for therapeutic development. Life science research accounts for approximately 35%, encompassing genomics, proteomics, and translational studies. Clinical research contributes roughly 25%, driven by pharmaceutical trials, biomarker validation, and precision medicine programs.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/biobanking-services-market?Juli

Regional Insights
North America leads the market with around 40% share, supported by the U.S. and Canada's advanced healthcare ecosystem, extensive genomic research programs, and strong regulatory frameworks promoting biobank development.

Europe accounts for approximately 30%, with countries such as Germany, the UK, and the Netherlands investing heavily in translational research, precision medicine, and automated biobanking technologies.

Asia-Pacific represents roughly 20%, driven by increasing R&D investments, rising prevalence of chronic diseases, and expansion of contract research organizations in China, Japan, India, and Southeast Asia.

Market Dynamics: Drivers, Restraints, and Opportunities

The global biobanking services market is being driven primarily by the growing demand for personalized medicine and precision healthcare. Biobanks provide high-quality biospecimens that are critical for biomarker discovery, drug development, and diagnostics, enabling patient-specific treatment strategies. For example, in 2025, UK Biobank released data on 3,000 circulating proteins from 54,000 participants, which facilitated groundbreaking studies in disease risk assessment. As healthcare systems and pharmaceutical companies increasingly focus on precision interventions, investments in biobank infrastructure, advanced sample storage, and integrated data platforms have surged. The integration of genomic, proteomic, and metabolomic research into clinical practice further underscores the indispensable role of biobanks in modern, data-driven healthcare.

Another key driver is the increasing government and private funding for biobanking initiatives. Governments are establishing national and regional programs to advance public health research, disease prevention, and personalized medicine, while private pharmaceutical and biotechnology firms are investing in biobanking infrastructure to accelerate drug discovery. This funding enables the development of automated, high-throughput biorepositories, supports large-scale population-based projects, and promotes public-private collaborations to improve sample diversity and quality.

However, the market faces restraints due to the high cost of biobanking infrastructure and maintenance. Establishing a modern biobank requires significant capital investment in ultra-low temperature freezers, cryogenic storage tanks, liquid nitrogen systems, automated sample handling equipment, and secure laboratory facilities. Compliance with stringent regulatory standards further increases complexity and expense. Maintaining these facilities involves ongoing costs for electricity, instrument calibration, backup systems, consumables, skilled personnel, and data security, limiting adoption among small- and mid-sized institutions and biobanks in low- and middle-income countries. The lack of stable funding models and limited revenue-generation opportunities further constrains global expansion.

At the same time, advancements in automated and robotic biobanking systems present a major opportunity. Automation enables high-throughput, precise handling of biological samples, reduces human error, and enhances operational efficiency. Robotic systems integrate workflows such as labeling, inventory management, environmental control, and secure data linkage, making large-scale biobanks more scalable and reliable. As the volume of clinical and research biospecimens continues to grow, automation and robotics are becoming essential for efficiency, cost reduction, and faster turnaround times, driving the evolution of the global biobanking services market.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.